Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability and PK of PF-06372865 in Healthy Subjects
NCT02070289Phase 1Completed
- Sponsor
- Pfizer
- Start
- Mar 2014
- Primary completion
- Jul 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of darigabat in epilepsy and anxiety disorder (6 cohorts), sponsored by Pfizer. Primary endpoints: Maximum Observed Plasma Concentration at 14 days, Area Under the Curve from Time Zero to end of dosing interval at 14 days and 1 more. Started Mar 2014; status: completed.
02
Drugs
darigabat
03
Conditions
epilepsyanxiety disorder
Beyond the preview
Go deeper on NCT02070289.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02070289.